OBJECTIVE: In order to improve adherence to treatment guidelines and performance indicators advocating tight control of disease activity in rheumatoid arthritis (RA), it is important to gain insight into the factors influencing rheumatologists' decisions whether or not to escalate care. Our objective was to determine the influence of specific attributes relative to a validated measure of disease activity (the Disease Activity Score [DAS]) on rheumatologists' decisions to escalate care. METHODS: We used a computer-based choice-based conjoint analysis survey to determine the relative importance of 6 attributes on rheumatologists' decisions related to escalation of care in RA. We administered the survey in a convenience sample of rheumatologists attending the 2008 American College of Rheumatology Annual Scientific Meeting. Utilities were calculated using hierarchical Bayes modeling, and these results were used to calculate the relative importance of each attribute. RESULTS: Rheumatologists assigned the most importance to the DAS score (relative importance of 30.7%) in their decision to escalate care. The age of the patient (21.5%) and erosions (20.5%) were rated as equally important in this decision. The decision to escalate care was least influenced by change in symptoms reported by the patient (11.1%), current treatment (8.9%), and disease duration (7.4%). CONCLUSION: Our findings suggest that rheumatologists endorse the DAS as a means to guide decision making in RA. We also found that age and erosions are important influences on rheumatologists' decisions to escalate care in RA. Our results add to the literature supporting age bias in RA and suggest that further research is needed to determine how age affects quality of care in clinical practice.
OBJECTIVE: In order to improve adherence to treatment guidelines and performance indicators advocating tight control of disease activity in rheumatoid arthritis (RA), it is important to gain insight into the factors influencing rheumatologists' decisions whether or not to escalate care. Our objective was to determine the influence of specific attributes relative to a validated measure of disease activity (the Disease Activity Score [DAS]) on rheumatologists' decisions to escalate care. METHODS: We used a computer-based choice-based conjoint analysis survey to determine the relative importance of 6 attributes on rheumatologists' decisions related to escalation of care in RA. We administered the survey in a convenience sample of rheumatologists attending the 2008 American College of Rheumatology Annual Scientific Meeting. Utilities were calculated using hierarchical Bayes modeling, and these results were used to calculate the relative importance of each attribute. RESULTS: Rheumatologists assigned the most importance to the DAS score (relative importance of 30.7%) in their decision to escalate care. The age of the patient (21.5%) and erosions (20.5%) were rated as equally important in this decision. The decision to escalate care was least influenced by change in symptoms reported by the patient (11.1%), current treatment (8.9%), and disease duration (7.4%). CONCLUSION: Our findings suggest that rheumatologists endorse the DAS as a means to guide decision making in RA. We also found that age and erosions are important influences on rheumatologists' decisions to escalate care in RA. Our results add to the literature supporting age bias in RA and suggest that further research is needed to determine how age affects quality of care in clinical practice.
Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans Journal: Arthritis Rheum Date: 2005-11
Authors: Heidi Mäkinen; Hannu Kautiainen; Pekka Hannonen; Timo Möttönen; Marjatta Leirisalo-Repo; Leena Laasonen; Markku Korpela; Harri Blåfield; Mikko Hakola; Tuulikki Sokka Journal: J Rheumatol Date: 2006-12-15 Impact factor: 4.666
Authors: Michael H Schiff; Elaine B Yu; Michael E Weinblatt; Larry W Moreland; Mark C Genovese; Barbara White; Amitabh Singh; Yun Chon; J Michael Woolley Journal: Drugs Aging Date: 2006 Impact factor: 3.923
Authors: Joan M Bathon; Roy M Fleischmann; Désirée Van der Heijde; John R Tesser; Paul M Peloso; Yun Chon; Barbara White Journal: J Rheumatol Date: 2006-02 Impact factor: 4.666
Authors: Christopher V Almario; Michelle S Keller; Michelle Chen; Karen Lasch; Lyann Ursos; Julia Shklovskaya; Gil Y Melmed; Brennan M R Spiegel Journal: Am J Gastroenterol Date: 2017-12-05 Impact factor: 10.864
Authors: Yomei Shaw; Chung-Chou H Chang; Marc C Levesque; Julie M Donohue; Kaleb Michaud; Mark S Roberts Journal: Arthritis Care Res (Hoboken) Date: 2018-04-16 Impact factor: 4.794
Authors: Roman Shrestha; Pramila Karki; Frederick L Altice; Oleksandr Dubov; Liana Fraenkel; Tania Huedo-Medina; Michael Copenhaver Journal: AIDS Behav Date: 2018-04
Authors: L T C van Hulst; W Kievit; R van Bommel; P L C M van Riel; L Fraenkel Journal: Arthritis Care Res (Hoboken) Date: 2011-10 Impact factor: 4.794
Authors: Veena K Ranganath; Paul Maranian; David A Elashoff; Thasia Woodworth; Dinesh Khanna; Theodore Hahn; Catherine Sarkisian; Joel M Kremer; Daniel E Furst; Harold E Paulus Journal: Rheumatology (Oxford) Date: 2013-06-27 Impact factor: 7.580